Literature DB >> 31677111

Female Androgenetic Alopecia: An Update on Diagnosis and Management.

Michela Starace1, Gloria Orlando2, Aurora Alessandrini1, Bianca Maria Piraccini3.   

Abstract

Female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women. The onset may be at any age following puberty and the frequency increases with age. Clinically, it shows a diffuse hair thinning over the central scalp, while the frontal hairline is usually retained. FAGA can have a significant psychological impact, leading to anxiety and depression. For this reason, early diagnosis is very important to stop the progression of the disease. The sex hormonal milieu is the main pathogenetic mechanism studied in FAGA. The role of androgens is not clearly defined and only one-third of women with FAGA show abnormal androgen levels. Endocrinological diseases with hyperandrogenism associated with FAGA comprise polycystic ovarian syndrome (PCOS), hyperprolactinemia, adrenal hyperplasia and, rarely, ovarian and adrenal tumours. Usually the diagnosis of FAGA is made clinically. A complete clinical examination and a blood examination can reveal other signs of hyperandrogenism. Trichoscopy shows the typical hair miniaturization. A scalp biopsy can be useful when the clinical evaluation does not provide a definitive diagnosis or when cicatricial alopecias with hair loss in the distribution of FAGA or alopecia areata are suspected. FAGA is a slowly progressive disease. The goal of therapy is to stop the progression and to induce a cosmetically acceptable hair regrowth. The most important drugs are topical minoxidil and oral anti-androgens. The purpose of this review is to provide an update on FAGA and to create a guideline on diagnosis and management of this frequent hair disease, not always easily recognizable from cicatricial alopecias with a similar distribution.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31677111     DOI: 10.1007/s40257-019-00479-x

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  8 in total

1.  Development and Validation of a Dermoscopic Severity Score for Female Pattern Hair Loss.

Authors:  Mariana Álvares Penha; Paulo Müller Ramos; Vinícius de Souza; Helio Amante Miot
Journal:  Skin Appendage Disord       Date:  2021-12-14

2.  Evaluation of dry eye and Meibomian gland dysfunction in female androgenetic alopecia patients.

Authors:  Pelin Kiyat; Melis Palamar; Bengu Gerceker Turk; Ayse Yagci
Journal:  Int Ophthalmol       Date:  2021-07-09       Impact factor: 2.031

Review 3.  Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle.

Authors:  Silvia Tampucci; Valentina Paganini; Susi Burgalassi; Patrizia Chetoni; Daniela Monti
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

4.  Epidemiology and disease burden of androgenetic alopecia in college freshmen in China: A population-based study.

Authors:  Fanping He; Minxue Shen; Zhixiang Zhao; Yicong Liu; Shuping Zhang; Yan Tang; Hongfu Xie; Xiang Chen; Ji Li
Journal:  PLoS One       Date:  2022-02-16       Impact factor: 3.240

5.  Anxiety and depression prevalence and their risk factors in lupus nephritis patients: A case-control study.

Authors:  Ying Hu; Ge Zhan
Journal:  Immun Inflamm Dis       Date:  2022-09

6.  Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire.

Authors:  Dursun Turkmen; Nihal Altunisik; Serpil Sener; Cemil Colak
Journal:  Dermatol Ther       Date:  2020-07-16       Impact factor: 3.858

7.  Management of telogen effluvium during the COVID-19 emergency: Psychological implications.

Authors:  Nicolò Rivetti; Stefania Barruscotti
Journal:  Dermatol Ther       Date:  2020-06-05       Impact factor: 3.858

Review 8.  Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment for Female Androgenetic Alopecia: Review of the Literature.

Authors:  Santo Raffaele Mercuri; Giovanni Paolino; Matteo Riccardo Di Nicola; Laura Vollono
Journal:  Medicina (Kaunas)       Date:  2021-03-25       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.